[Clinical evaluation of fluoxetine].
The multicenter trials were performed in a group of 86 depressive inpatients (among them 64 with endogenous depression) managed with fluoxetine (Prozac). It was established that the drug is most effective in managing psychogenic depressions and may also be of use in endogenous depressions, among them in drug resistant ones. Tolerance to the drug was satisfactory, 62% did not show any unwanted side-effects. The rest of the group displayed sleep disorders, increased anxiety, lost of appetite and nausea. Changes in the laboratory parameters and non-specific changes in the electrocardiogram were observed sporadically. Fluoxetine seemed not to have any direct cholinolytic effect.
Puzyński
S
S
II Kliniki Psychiatrycznej, Instytutu Psychiatrii i Neurologii w Warszawie.
Rybakowski
J
J
Kocur
J
J
Rydzyński
Z
Z
Beresewicz
M
M
Bogdanowicz
E
E
Duszyk
S
S
Gruszczyński
W
W
Kalinowski
A
A
Koszewska
I
I
D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D005473:Fluoxetine
Ocena kliniczna fluoksetyny (wyniki badań wieloośrodkowych).